Navigation Links
MD Bioproducts Releases a New Mouse T1/ST2 ELISA
Date:3/29/2010

New ELISA offers a rapid method to quantitate T1/ST2 from mouse serum and cell culture supernate samples.

(PRWEB) March 24, 2010 -- MD Bioproducts, a division of MD Biosciences, Inc announces the launch of its new Mouse T1/ST2 ELISA for the study of inflammatory conditions. The ELISA offers researchers a rapid and accurate method to measure mouse serum and cell culture supernate levels of T1/ST2. The assay measures samples in the range of 0.156 – 10 ng/mL with a sensitivity of 0.05 ng/mL. Results can be obtained in less than 3 hours. In addition to the T1/ST2 ELISA, MD Bioproducts also offers researchers T1/ST2 antibodies for other related research applications such as IHC, western blotting, and flow cytometry.

ST2, also know as IL-1 R4 and T1 is an interleukin-1 receptor family glycoprotein that contributes to Th2 immune responses. ST2 is expressed on the surface of mast cells, activated Th2 cells, macrophages and cardio myocytes. It binds IL-33, a cytokine that is up regulated by inflammation or mechanical strain in smooth muscle cells, keratinocytes, airway epithelia and cardiac fibroblasts. The soluble ST2 isoform is released by activated Th2 cells and strained cardiac myocytes and is elevated in the serum in allergic asthma. The roles of T1/ST2 and IL-33 have been investigated in many immune responses such as allergy, asthma, rheumatoid arthritis and osteoarthritis.

About MD Bioproducts
MD Bioproducts is a division of the privately-owned company MD Biosciences, Inc. offering products for use in the inflammations, neurology, endocrinology, and metabolic disorders research fields. Since beginning operations in the U.S., based out of St. Paul, Minnesota, MD Biosciences has experienced significant development and grown to a company of 60 employees.

About MD Biosciences
MD Biosciences provides pre-clinical contract research services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

###

Read the full story at http://www.prweb.com/releases/mdbioproducts/ST2ELISA/prweb3769704.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
2. Microbia PE Bolsters Senior Management Team; Positions Company for Commercializing Proprietary Bioproducts
3. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
4. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
5. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
6. ARUP Laboratories Releases ARUP Consult(R) 2.0
7. Rabobank Releases Annual North American Food & Agribusiness Outlook
8. National Nanotechnology Initiative releases new strategic plan
9. Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI
10. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
11. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
MD Bioproducts Releases a New Mouse T1/ST2 ELISA
(Date:2/23/2017)... /PRNewswire/ - The Fight Against Cancer Innovation Trust (FACIT) ... pleased to report that Fusion Pharmaceuticals Inc. (Fusion) has ... Johnson Innovation – JJDC, Inc. (JJDC) as the lead ... Biotechnology Partners, and Genesys Capital, as well as founding ... ...
(Date:2/23/2017)...  Imanis Life Sciences announced today the launch ... viruses for virotherapy research. These viruses are licensed ... vaccinia virus-based technology platform for research use. ... partnership with Genelux to offer researchers, for the ... in research," said Dr. Kah Whye Peng ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... insulin, cortisol, CRP, adiponectin, uric acid, and/or other biomarkers or SNPs of interest) ... from Salimetrics’ SalivaLab , the relationship between insulin and other relevant biomarkers ...
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017   ... Beyond Type 1, a not-for-profit advocacy and education group ... a grant from Beyond Type 1 to support ViaCyte,s ... and other insulin-requiring diabetes.  For more ... cell-derived cell replacement therapies with a focus on the ...
Breaking Biology Technology:
(Date:2/1/2017)... February 1, 2017 IDTechEx Research, a leading ... technology, announces the availability of a new report, Sensors for ... Continue Reading ... ... collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and ...
(Date:1/26/2017)... 2017  Crossmatch, a leading provider of security and ... at combatting fraud, waste and abuse in assistance operations ... Action on Disaster Relief conference in Panama ... agencies and foreign assistance organizations throughout Latin ... are a largely unacknowledged problem in the foreign assistance ...
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
Breaking Biology News(10 mins):